Next Article in Journal
Antibody Fragments Defining Biologically Relevant Conformations of Target Proteins
Previous Article in Journal
Reduced Culture Temperature Differentially Affects Expression and Biophysical Properties of Monoclonal Antibody Variants
Article Menu

Export Article

Addendum published on 22 September 2015, see Antibodies 2015, 4(3), 278.

Open AccessArticle
Antibodies 2014, 3(4), 272-288; doi:10.3390/antib3040272

Polyclonal Antibody Therapies for Clostridium difficile Infection

Secretory IgA, Inc., Ann Arbor, and Allergy and Clinical Immunology, William Beaumont Hospital, Royal Oak, MI 48073, USA
Secretory IgA, Inc., Ann Arbor, MI, USA
Secretory IgA, Inc., Ann Arbor, MI, USA
Author to whom correspondence should be addressed.
Received: 26 August 2014 / Revised: 18 September 2014 / Accepted: 28 September 2014 / Published: 28 October 2014
(This article belongs to the Special Issue Antibodies Therapies against Infectious Diseases)
View Full-Text   |   Download PDF [2869 KB, uploaded 28 October 2014]   |  


Clostridium difficile infection has emerged as a growing worldwide health problem. The colitis of Clostridium difficile infection results from the synergistic action of C. difficile secreted toxins A and B upon the colon mucosa. A human monoclonal IgG anti-toxin has demonstrated the ability in combination therapy to reduce mortality in C. difficile challenged hamsters. This antibody is currently in a clinical trial for the treatment of human Clostridium difficile infection. More than one group of investigators has considered using polyclonal bovine colostral antibodies to toxins A and B as an oral passive immunization. A significant proportion of the healthy human population possesses polyclonal antibodies to the Clostridium difficile toxins. We have demonstrated that polyclonal IgA derived from the pooled plasma of healthy donors possesses specificity to toxins A and B and can neutralize these toxins in a cell-based assay. This suggests that secretory IgA prepared from such pooled plasma IgA may be able to be used as an oral treatment for Clostridium difficile infection. View Full-Text
Keywords: Clostridium difficile; toxins A and B; polyclonal IgG; monoclonal IgG; polyclonal IgA; secretory IgA Clostridium difficile; toxins A and B; polyclonal IgG; monoclonal IgG; polyclonal IgA; secretory IgA

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Simon, M.R.; Chervin, S.M.; Brown, S.C. Polyclonal Antibody Therapies for Clostridium difficile Infection. Antibodies 2014, 3, 272-288.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top